VIRAGENESIS | VIRAL RESERVOIRS, TRIGGERS, & CO-FACTORS

Document Code: VIR-SCF-RTC-2025

Section I. Viral Reservoirs

Reservoir	Examples	SCF Fault Tier Impact	PCR Intervention Strategy
Endogenous Retroviral Elements (ERVs)	HERV-W, HERV-K, LINE-1	Tier 1 epigenetic drift; latent transcriptional fault nodes	Preventative: Epigenetic stabilization (methyl donors, HDAC modulators)
Curative: Antisense oligonucleotides, CRISPR excision
Restorative: Immunomodulation for tolerance reset
Latent DNA Viruses	EBV (B-cells), HHV-6 (CNS), CMV	Tier 3–5 immune docking and metabolic disruption	Preventative: Vaccination (EBV, CMV)
Curative: Antivirals (valganciclovir, acyclovir) Restorative: B-cell depletion (rituximab) with immune recalibration
Retroviral Reservoirs	HIV (CD4⁺ T-cells), HTLV-1	Tier 2–4 bioenergetic collapse, immune loop distortion	Preventative: Early ART initiation
Curative: Shock-and-kill or block-and-lock latency control Restorative: Mitochondrial repair (NAD⁺ boosters, ROS quenchers)
Tissue-Specific Viral Niches	JC virus (oligodendrocytes), BK virus (renal), SARS-CoV-2 (gut/brain)	Tier 3 ECM remodeling & immune desynchrony	Preventative: Surveillance (PCR/antibody panels)
Curative: Targeted antivirals (SARS-CoV-2 protease inhibitors, JCV-directed therapies) Restorative: ECM stabilizers, neurorepair stacks

Section II. Viral Triggers

Trigger	Examples	SCF Fault Tier Impact	PCR Intervention Strategy
Epigenetic Derepression	Loss of H3K9me3, DNA hypomethylation	Tier 1 ERV activation	P: Epigenetic stabilizers
C: Demethylation reversal compounds
R: DNA repair enhancers
Oxidative Stress	Viral infection, hypoxia, metabolic overload	Tier 2 redox instability	P: ROS buffering (N-acetylcysteine, CoQ10)
C: Acute antioxidant therapy
R: NAD⁺ replenishment
Co-Infection	EBV + HERV-W; HIV + HBV/HCV	Amplified cascades across multiple tiers	P: Vaccines (HBV, HPV, SARS-CoV-2)
C: Combination antivirals
R: Immune recalibration (checkpoint modulators)
Latency Escape	Immunosuppression, aging	Tier 3–5 viral reactivation	P: Surveillance monitoring
C: Latency inhibitors/blockers
R: T-cell reconstitution
Environmental Exposures	Dioxins, radiation, heavy metals	Synergistic with viral activation	P: Environmental mitigation
C: Chelation/radioprotectors
R: ECM/immune recovery
Aging/Senescence	Telomere shortening, NAD⁺ decline	Viral–aging synergy	P: Anti-senescence (senolytics) C: Viral reactivation blockers
R: Longevity metabolic therapy

Section III. Viral Co-Factors

Co-Factor	Examples	SCF Fault Tier Impact	PCR Intervention Strategy
Immune Dysregulation	Treg skewing, checkpoint collapse	Tier 5 immune desynchrony	P: Immune monitoring
C: Immunotherapy (checkpoint inhibitors)
R: Treg balance
Metabolic Collapse	NAD⁺ depletion, mitochondrial dysfunction	Tier 2–3	P: Nutritional optimization
C: Mitochondrial rescue agents (nicotinamide riboside, mitophagy enhancers)
R: Bioenergetic resetting
ECM/Niche Vulnerability	Collagen breakdown, MMP activation	Tier 3–4 terrain tilt	P: Matrix protectors (collagen stabilizers, TIMPs)
C: Anti-fibrotic drugs
R: ECM regeneration therapies
Microbiome Imbalance	Gut/lung dysbiosis	Amplified immune signaling skew	P: Probiotics/prebiotics
C: Bacteriophage therapy
R: Microbiome transplantation
Genetic Susceptibility	HLA variants, TLR polymorphisms	Defines resilience zones	P: Genomic risk screening
C: Personalized antivirals
R: Gene therapy correction
Lifestyle/Stress	Sleep loss, trauma, poor diet	Epigenetic destabilization	P: Behavioral interventions
C: Stress-modulating drugs
R: Neuroimmune recalibration

Section IV. Integrated RTC–PCR Framework

Reservoirs = latent persistence
Triggers = activation signals
Co-Factors = amplifiers of dysfunction

SCF-PCR Mapping:

Preventative (P): Upstream interception of viral activation nodes (epigenetic stabilization, vaccination, stress management).
Curative (C): Direct containment of viral expression/reactivation (antivirals, gene editing, checkpoint modulation).
Restorative (R): Downstream repair of systemic terrain tilt (immune recalibration, ECM rebuilding, neuroregeneration).

HYPOTHESIS-DRIVEN MAPPING | VIRAL RESERVOIRS, TRIGGERS, AND CO-FACTORS

Section I. Viral Reservoirs

Reservoir	Examples	SCF Fault Tier Impact	PCR Intervention Strategy
Endogenous Retroviral Elements (ERVs)	HERV-W, HERV-K, LINE-1	Tier 1 epigenetic drift; latent transcriptional fault nodes	Preventative: Epigenetic stabilization (methyl donors, HDAC modulators)
Curative: Antisense oligonucleotides, CRISPR excision
Restorative: Immunomodulation for tolerance reset
Latent DNA Viruses	EBV (B-cells), HHV-6 (CNS), CMV	Tier 3–5 immune docking and metabolic disruption	Preventative: Vaccination (EBV, CMV)
Curative: Antivirals (valganciclovir, acyclovir) Restorative: B-cell depletion (rituximab) with immune recalibration
Retroviral Reservoirs	HIV (CD4⁺ T-cells), HTLV-1	Tier 2–4 bioenergetic collapse, immune loop distortion	Preventative: Early ART initiation
Curative: Shock-and-kill or block-and-lock latency control Restorative: Mitochondrial repair (NAD⁺ boosters, ROS quenchers)
Tissue-Specific Viral Niches	JC virus (oligodendrocytes), BK virus (renal), SARS-CoV-2 (gut/brain)	Tier 3 ECM remodeling & immune desynchrony	Preventative: Surveillance (PCR/antibody panels)
Curative: Targeted antivirals (SARS-CoV-2 protease inhibitors, JCV-directed therapies) Restorative: ECM stabilizers, neurorepair stacks

Section II. Viral Triggers

Trigger	Examples	SCF Fault Tier Impact	PCR Intervention Strategy
Epigenetic Derepression	Loss of H3K9me3, DNA hypomethylation	Tier 1 ERV activation	P: Epigenetic stabilizers
C: Demethylation reversal compounds
R: DNA repair enhancers
Oxidative Stress	Viral infection, hypoxia, metabolic overload	Tier 2 redox instability	P: ROS buffering (N-acetylcysteine, CoQ10)
C: Acute antioxidant therapy
R: NAD⁺ replenishment
Co-Infection	EBV + HERV-W; HIV + HBV/HCV	Amplified cascades across multiple tiers	P: Vaccines (HBV, HPV, SARS-CoV-2)
C: Combination antivirals
R: Immune recalibration (checkpoint modulators)
Latency Escape	Immunosuppression, aging	Tier 3–5 viral reactivation	P: Surveillance monitoring
C: Latency inhibitors/blockers
R: T-cell reconstitution
Environmental Exposures	Dioxins, radiation, heavy metals	Synergistic with viral activation	P: Environmental mitigation
C: Chelation/radioprotectors
R: ECM/immune recovery
Aging/Senescence	Telomere shortening, NAD⁺ decline	Viral–aging synergy	P: Anti-senescence (senolytics) C: Viral reactivation blockers
R: Longevity metabolic therapy

Section III. Viral Co-Factors

Co-Factor	Examples	SCF Fault Tier Impact	PCR Intervention Strategy
Immune Dysregulation	Treg skewing, checkpoint collapse	Tier 5 immune desynchrony	P: Immune monitoring
C: Immunotherapy (checkpoint inhibitors)
R: Treg balance
Metabolic Collapse	NAD⁺ depletion, mitochondrial dysfunction	Tier 2–3	P: Nutritional optimization
C: Mitochondrial rescue agents (nicotinamide riboside, mitophagy enhancers)
R: Bioenergetic resetting
ECM/Niche Vulnerability	Collagen breakdown, MMP activation	Tier 3–4 terrain tilt	P: Matrix protectors (collagen stabilizers, TIMPs)
C: Anti-fibrotic drugs
R: ECM regeneration therapies
Microbiome Imbalance	Gut/lung dysbiosis	Amplified immune signaling skew	P: Probiotics/prebiotics
C: Bacteriophage therapy
R: Microbiome transplantation
Genetic Susceptibility	HLA variants, TLR polymorphisms	Defines resilience zones	P: Genomic risk screening
C: Personalized antivirals
R: Gene therapy correction
Lifestyle/Stress	Sleep loss, trauma, poor diet	Epigenetic destabilization	P: Behavioral interventions
C: Stress-modulating drugs
R: Neuroimmune recalibration

Section IV. Integrated RTC–PCR Framework

Reservoirs = latent persistence

Triggers = activation signals

Co-Factors = amplifiers of dysfunction

SCF-PCR Mapping:

Preventative (P): Upstream interception of viral activation nodes (epigenetic stabilization, vaccination, stress management).

Curative (C): Direct containment of viral expression/reactivation (antivirals, gene editing, checkpoint modulation).

Restorative (R): Downstream repair of systemic terrain tilt (immune recalibration, ECM rebuilding, neuroregeneration).